Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Importance Lipoprotein (a)(Lp [a]) is associated with atherosclerotic disease and aortic
stenosis. Lp (a) forms by bonding between apolipoprotein (a)(apo [a]) and apo B 100 …

Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

Cardiovascular disease is the leading cause of death in women and men globally, with most
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 …

Importance Epidemiological and genetic data have implicated lipoprotein (a) as a potentially
modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no …

Compelling evidence supports a causal role for lipoprotein (a)(Lp (a)) in cardiovascular
disease. No pharmacotherapies directly targeting Lp (a) are currently available for clinical …

Importance Lipoprotein (a)(Lp [a]) is a low-density lipoprotein (LDL) cholesterol–like particle
bound to apolipoprotein (a). This novel marker of cardiovascular disease acts through …

Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …